THE INDUSTRY’S LARGEST MARKETPLACE FOR PHARMACEUTICALS
steroidify.xyz has been in operation for almost 30 years, acquiring 50’s of thousands of satisfied customers.
steroidify.xyz works very hard to establish trust with our customer. Our high-quality products and professional staff is testament to the legitimacy of our business practice.
Each brand is hand-selected and goes through a very thorough review process.
Quality is held in a very high regard at steroidify.xyz. To further legitimize these products, we do have a comprehensive
Featured
Ultima-Proviron
ACTIVE HALF-LIFE 12 hours CLASSIFICATION Anabolic Steroid DOSAGE Men 25-100 mg/day ACNE Yes WATER RETENTION ..
Raloxiheal
ACTIVE HALF-LIFE: 24 hours CLASSIFICATION: Selective Estrogen Receptor Modulator (SERM) ACNE: Not present WATER RETEN..
HGH Fragment 176-191
PRODUCT CLASSIFICATION Growth Hormone ACNE No WATER RETENTION No HBR No HEPATOTOXICITY No ..
Nandrolone Phenylpropionate
ACTIVE HALF-LIFE 4-5 days CLASSIFICATION Anabolic Steroid DOSAGE Recommended for Men: 200-600 mg/week ACNE ..
MK2866 & LGD
ACTIVE HALF-LIFE 24-36 hours CLASSIFICATION SARM DOSAGE 25-50 mg/day ACNE No WATER RETENTION ..
3-Test 350 Blend
ACTIVE HALF-LIFE 7-8 Days CLASSIFICATION Anabolic Steroid DOSAGE Men: 300-1500 mg/week ACNE Yes WATER RETENTION Yes HBR ..
Thymalin
PRODUCT CLASSIFICATION Polypeptide Hormone ACNE-FREE FORMULA No WATER RETENTION None HBR (Hydrochloride) N..
Arimistane
ACTIVE HALF-LIFE 2-4 hours CLASSIFICATION Aromatase Inhibitor DOSAGE 50 mg/day ACNE No WATER R..
HCG
CLASSIFICATION Gonadotropins DOSAGE 500-3000 IU, administered 1-3 times per week ACNE No WATER RETENTION No HBR No HEPATOTOXICITY No AROMATIZATI..
GHRP-6
ACTIVE HALF-LIFE 2.5 hours CLASSIFICATION Peptide Hormone DOSAGE 100-300 mcg/day ACNE No WATER RETENTION Y..
CEC 1000
MANUFACTURER Basel WAREHOUSE International Warehouse 2 ACTIVE INGREDIENT Cefaclor Key Benefits of CEC 1000 mg Eff..
Tadasoft-20
ACTIVE HALF-LIFE 24-36 Hours CLASSIFICATION PDE5 Inhibitor DOSAGE Recommended for Men: 10-20mg/day ACNE None W..












